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Muscle first in neurodegenerative disease?
R
esearchers hunting for the molecular malfunction behind the paralyzing disease spinal 
muscular atrophy (SMA) might have been looking on the wrong side of the neuromuscular 
junction, as Rajendra et al. show on page 831. The work suggests that reduced levels of 
SMA’s signature protein, SMN, disrupt the junction from the muscle side.
SMA is the second most prevalent fatal recessive illness after cystic fi  brosis. Although its severity 
varies, the disease often kills patients before age two as motoneurons 
deteriorate and muscles wither. How reduced amounts of SMN trigger 
symptoms isn’t clear. Because the disease involves neural breakdown, 
researchers have assumed that the loss of SMN mainly hits moto  neurons, 
not muscles.
To model the disease, Rajendra et al. identifi  ed fruit fl  ies that produce 
too little of the protein. Feeble fl  ight muscles grounded the mutants. 
Consistent with previous mouse models, the neurons that innervate these 
weakened muscles grew and branched abnormally. In addition, the 
insects’ fl  ight muscles lacked actin, a sign that innervation had failed.
Localization experiments suggested SMN is crucial specifi  cally in   
muscles. The researchers determined that, in normal fl  ies, SMN accumulates 
in muscle sarcomeres and gloms onto α-actinin, which interlinks actin 
fi  laments. Although the results do not rule out the “neuron fi  rst” hypothesis, 
they suggest that muscle dysfunction helps spur nerve deterioration.
A sloppy checkpoint
I
f the G2 checkpoint were a building in-
spector, it would get fi  red for negligence. 
Deckbar et al. show on page 749 that the 
checkpoint, which is supposed to halt division af-
ter chromosome damage, allows cells to proceed 
into mitosis even if they harbor fractured DNA.
The G2 checkpoint interrupts the cell cycle 
to allow repair of double-stranded DNA breaks 
(DSBs). But the checkpoint isn’t perfect, as the 
researchers found when they irradiated normal 
human fi  broblasts and Artemis cells, which have 
a normal checkpoint but sluggish DSB repair. 
Each of the cells that went on into mitosis had 
one to two chromosome breaks, which is 10 times 
the background value.
Not every DSB shows up as a complete 
chromosome break. So to gauge the number of 
DSBs that are slipping past the checkpoint, the 
researchers counted the number of repair foci, 
where enzymes have begun—but not fi  nished—
mending DNA. Fibroblasts left G2 with  20 
foci. Other methods gave similar values for 
unfi   xed DSBs, indicating that the checkpoint 
has a threshhold of  10 to 20 breaks.
Only one DSB is needed to activate this check-
point in yeast, according to previous studies. Mam-
malian cells might be sloppier because they carry 
much more DNA. Whether unrepaired breaks 
cause trouble is unclear. Many of them might get 
fi  xed at the subsequent G1 checkpoint.
Die another way
O
n page 853 Ueda et al. describe a protein that switches cells 
between two death mechanisms, preventing necrosis while pro-
moting apoptosis. The molecule might provide a new way to 
save brain cells after a stroke.
A stroke delivers a double whammy. First, cells near the clot begin to 
perish from necrosis, which is triggered by ATP scarcity. Later, more distant 
cells start dying through apoptosis. Although 
anti-apoptosis compounds can stem some 
damage, their beneﬁ   ts are modest, possibly 
because the necrosis is more devastating. 
Molecules to halt necrosis have proven elusive.
Ueda et al. found one such molecule in 
cultures of rat cortical neurons. The protein 
ProTα curbs necrosis in cultures that lack 
  serum or have been oxygen deprived. But 
it also boosts their apoptotic death rates. 
Adding growth factors that derail apoptosis 
protects most of the cells.
The group showed that ProTα works by 
keeping cells well-nourished. During necrosis, 
some of the GLUT transporters that usher glu-
cose into the cell exit the plasma membrane. 
But ProTα prevents this relocation.
Ueda et al. conclude that ProTα ﬂ  ips 
cells from an uncontrollable form of cell 
death, necrosis, to a more controllable one. 
Other factors can derail cells from apoptosis. 
A treatment that mixes ProTα with some of 
these compounds might spare neurons after 
a stroke.
SMN (red) congregates at the actin-rich I-bands (green) in 
muscle ﬁ  bers.
The characteristic signs of 
necrosis (top) are missing 
in a neuron dosed with 
ProT𝗂 (bottom).